Lacosamide

證據等級: L5

預測適應症: 10 個

Lacosamide: From Focal Epilepsy to Manic Bipolar Affective Disorder

One-Sentence Summary

Lacosamide (Vimpat®) is a third-generation antiepileptic drug approved globally for focal (partial-onset) seizures, currently not marketed in Taiwan. The TxGNN model predicts it may be effective for Manic Bipolar Affective Disorder, with 1 clinical trial and 8 relevant publications currently supporting this direction.

Multi-Indication Pack Note: This Evidence Pack covers 10 predicted indications. The highest-evidence candidate is Migraine Disorder (TxGNN Rank 5, L1 evidence, 3 completed Phase 3 RCTs, recommendation: Proceed with Guardrails), which merits a separate focused evaluation report.

Quick Overview

Item	Content
Original Indication	Focal (partial-onset) epilepsy
Predicted New Indication	Manic Bipolar Affective Disorder
TxGNN Prediction Score	99.96%
Evidence Level	L3
Taiwan Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Research Question

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this evidence pack. Based on well-established pharmacology, Lacosamide operates through a dual mechanism: (1) selective enhancement of slow inactivation of voltage-gated sodium (Nav) channels, reducing pathological neuronal hyperexcitability in a use-dependent manner distinct from older AEDs; and (2) binding to CRMP2 (Collapsin Response Mediator Protein 2), a phosphoprotein involved in synaptic plasticity, axonal growth, and neurodevelopment. This dual action profile gives Lacosamide a pharmacological fingerprint that extends beyond simple seizure suppression.

The mechanistic link to bipolar disorder is well-grounded in precedent: multiple AEDs already serve as first-line mood stabilizers. Valproate and lamotrigine—both Nav modulators—are guideline-recommended treatments for bipolar disorder. Lacosamide’s Nav slow-inactivation mechanism represents a direct pharmacological parallel, suggesting it may similarly dampen the abnormal limbic circuit hyperexcitability underlying mood cycling. Additionally, CRMP2 modulation may influence synaptic remodeling pathways relevant to mood dysregulation, providing a second mechanistic rationale beyond sodium channel effects alone.

However, a critical nuance must be flagged: existing clinical evidence (including the only Phase 3 trial, NCT07412132) targets bipolar depression rather than the manic phase specifically. TxGNN predicts efficacy for “manic bipolar affective disorder,” yet no study has directly addressed mania. This phenotypic mismatch between the model’s prediction and the studied clinical target is the primary gap that must be resolved before this repurposing direction can advance.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT07412132	Phase 3	Recruiting	40	Evaluates lacosamide as augmentation to first- or second-line therapy for moderate-to-severe major depressive episodes in Bipolar Disorder Types I and II. Prior open-label data demonstrated improvement in both depressive and manic symptoms. Completion expected January 2027. Caveat: targets the depressive phase, not the manic phase; enrollment of 40 is unusually small for a Phase 3 trial.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
30251375	2018	Retrospective Comparison	Psychiatry Clin Neurosci	30-day comparison of lacosamide vs other anticonvulsants in hospitalized bipolar disorder patients without comorbid epilepsy; first controlled clinical data directly testing lacosamide in BD
33666402	2021	Open-label Pilot	J Clin Psychopharmacol	12-week open-label pilot assessing lacosamide efficacy and safety for bipolar depression; generated preliminary data that informed the subsequent Phase 3 trial
28845834	2017	Case Series	Acta Bio-medica	Clinical stabilization with lacosamide in mood disorder comorbid with PTSD and fronto-temporal epilepsy; highlights Nav slow-inactivation as a membrane-stabilizing mechanism with potential psychiatric benefit
29253680	2018	Prospective Multicenter	Epilepsy & Behavior	Lacosamide improved depression and anxiety scores in focal refractory epilepsy patients; improvement appeared partly independent of seizure control, suggesting a direct psychotropic effect
30275630	2018	Case Report	Indian J Psychol Med	Lacosamide-precipitated neutropenia in a bipolar disorder patient with comorbid epilepsy; important safety signal for haematological monitoring in psychiatric populations
32693579	2020	Mechanistic Review	ACS Chem Neurosci	Reviews CRMP2 as a druggable target in neurological disorders; lacosamide’s CRMP2 binding may modulate synaptic plasticity pathways relevant to mood circuit dysfunction in BD
29957667	2018	Review	Ther Drug Monit	AED therapeutic drug monitoring 2018 update; explicitly notes that AEDs including lacosamide are applied in bipolar disorder, contextualizing its expanding psychiatric use
38304661	2024	Case Report	Cureus	Complex case of a pregnant patient with Bipolar Disorder I, epilepsy, and PNES managed with lacosamide; illustrates real-world psychiatric use complexity and safety considerations

Taiwan Market Information

Lacosamide is not currently approved or marketed in Taiwan (0 registered authorizations). Globally, the drug is marketed as Vimpat® (UCB Pharma) and holds regulatory approval from the US FDA (since 2008) and the EMA for focal epilepsy treatment in adults and adolescents aged 4 years and above. The absence of Taiwan registration means that any clinical development for bipolar disorder in Taiwan would require a new IND (Investigational New Drug) application to the TFDA, or alignment with an ongoing international development program.

Safety Considerations

Please refer to the SmPC for full safety information.

Signal from literature: One case report (PMID 30275630) documents lacosamide-precipitated neutropenia in a bipolar disorder patient. Although this is a single case, haematological monitoring (CBC with differential) may be warranted when lacosamide is used in psychiatric populations, particularly as standard epilepsy monitoring protocols may not be automatically applied in psychiatry settings.

Conclusion and Next Steps

Decision: Research Question

Rationale: Lacosamide has a biologically plausible mechanism for bipolar disorder (Nav slow-inactivation paralleling lamotrigine/valproate; CRMP2-mediated synaptic modulation), and preliminary data exists (one retrospective comparison, one open-label pilot). However, the evidence base remains pre-confirmatory: no Phase 3 results are yet available, sample sizes to date are very small, and—critically—existing studies address bipolar depression, not the manic phase that TxGNN specifically predicts.

To proceed, the following is needed:

Retrieve complete MOA data from DrugBank to formally characterize the Nav slow-inactivation kinetics and CRMP2 binding profile
Obtain full safety information (EMA SmPC or equivalent) covering cardiac conduction effects (PR-interval prolongation), teratogenicity, and haematological risks—all relevant to psychiatric populations
Clarify the clinical target phenotype: bipolar mania, bipolar depression, or both; TxGNN predicts the manic phenotype but current trials study depression
Await Phase 3 results from NCT07412132 (expected completion January 2027) before committing resources
If results are positive, design a dedicated RCT targeting manic or mixed bipolar episodes with adequate statistical power (n >100)

Higher-priority candidate within this pack: Migraine Disorder (predicted_indications[4]) carries L1 evidence with 2 completed Phase 3 RCTs directly comparing lacosamide to standard-of-care (propranolol, topiramate) and a mechanistic study demonstrating CGRP suppression. It is recommended to generate a dedicated evaluation report for the migraine indication as the primary near-term development priority.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.